CStone Pharmaceuticals ( (HK:2616) ) has shared an update.
CStone Pharmaceuticals has announced the successful dosing of the first patient in a global multicenter Phase I clinical trial for its innovative trispecific antibody, CS2009. This trial aims to evaluate CS2009’s potential in treating various advanced solid tumors, including non-small cell lung cancer and gastric adenocarcinoma. CS2009, which targets PD-1, VEGFA, and CTLA-4, has shown superior anti-tumor activity in preclinical studies compared to existing therapies. The trial’s initiation marks a significant milestone for CStone, potentially positioning CS2009 as a next-generation immunotherapy product with enhanced efficacy and safety for patients with low or negative PD-L1 expression.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing anti-cancer therapies. With a commitment to addressing unmet medical needs in China and globally, CStone has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. The company’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
YTD Price Performance: 49.13%
Average Trading Volume: 3,550,569
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.33B
Learn more about 2616 stock on TipRanks’ Stock Analysis page.